1. Home
  2. HRTG vs ERAS Comparison

HRTG vs ERAS Comparison

Compare HRTG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heritage Insurance Holdings Inc.

HRTG

Heritage Insurance Holdings Inc.

HOLD

Current Price

$24.63

Market Cap

898.0M

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$12.45

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRTG
ERAS
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
898.0M
1.0B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
HRTG
ERAS
Price
$24.63
$12.45
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$32.50
$5.78
AVG Volume (30 Days)
242.0K
5.9M
Earning Date
03-10-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
98.61
N/A
EPS
4.83
N/A
Revenue
$842,277,000.00
N/A
Revenue This Year
$5.45
N/A
Revenue Next Year
$7.27
N/A
P/E Ratio
$5.14
N/A
Revenue Growth
6.12
N/A
52 Week Low
$9.89
$1.01
52 Week High
$31.98
$12.69

Technical Indicators

Market Signals
Indicator
HRTG
ERAS
Relative Strength Index (RSI) 37.01 74.50
Support Level $24.23 $11.41
Resistance Level $25.87 $12.69
Average True Range (ATR) 1.02 0.72
MACD -0.07 -0.10
Stochastic Oscillator 21.71 87.35

Price Performance

Historical Comparison
HRTG
ERAS

About HRTG Heritage Insurance Holdings Inc.

Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance in various states in the United States. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. Company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: